Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors
Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major…
Aspirin Confers No Long-Term Heart Benefits in Older Adults
TOPLINE: Healthy older adults who received aspirin experienced no significant long-term benefits against major adverse cardiovascular events (MACE);…